You are here: Industry Insights > Market News > Pfizer in talks with India over expedited approval for COVID-19 vaccine

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Pfizer in talks with India over expedited approval for COVID-19 vaccine

expresspharmaMay 07, 2021

Tag: Pfizer , Albert Bourla , COVID-19 Vaccine

Favorites

Pfizer is in discussions with the Indian government seeking an “expedited approval pathway” for its COVID-19 vaccine, said Albert Bourla, the company’s CEO on LinkedIn, while announcing a donation of medicines worth more than $70 million.

Pfizer in talks with India over expedited approval for COVID-19 vaccine

“Unfortunately, our vaccine is not registered in India although our application was submitted months ago,” he said.

He added, “We are currently discussing with the Indian government an expedited approval pathway to make our Pfizer-BioNTech vaccine available for use in the country.”

Previous:NATCO receives emergency-use approval for Baricitinib tablets for COVID-19 treatment

Next:Glenmark launches Ryaltris-AZ in India

Sartorius Collaborates with Sanofi to Commercialize End-To-End Platform for Downstream Process Intensification

Biotech NewswireMay 14, 2024

The life science group Sartorius is collaborating with biopharmaceutical company Sanofi to develop an end-to-end platform for integrated and continuous downstream bioprocessing.

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

Biotech NewswireMay 10, 2024

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

Biotech NewswireMay 09, 2024

Pfizer in talks with India over expedited approval for COVID-19 vaccine | Pharmasources.com

Glucagon-like peptide-1 (GLP-1) Receptor Agonist Semaglutide in an Oleogel Formulation Using the BrainDos™ Technology Significantly Increases Drug Delivery into Cells

Biotech NewswireMay 09, 2024

MetP Pharma AG, leveraging the proprietary nose-to-brain drug delivery technology BrainDos™ in internal and external product development and manufacturing programs.

Pfizer in talks with India over expedited approval for COVID-19 vaccine

Related News

Sartorius Collaborates with Sanofi to Commercialize End-To-End Platform for Downstream Process Intensification

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

Glucagon-like peptide-1 (GLP-1) Receptor Agonist Semaglutide in an Oleogel Formulation Using the BrainDos™ Technology Significantly Increases Drug Delivery into Cells

You may like